Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Groskopf

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Cancer Letters|November 25, 2010
PCA3: from basic molecular science to the clinical labJohn R Day, Matthias Jost, Mark A Reynolds, et al.
Cancer Letters|February 17, 2007
Molecular markers for prostate cancerMark A Reynolds, Kumar Kastury, Jack Groskopf, et al.
World Journal of Urology|May 3, 2023
Cost-effectiveness of an urinary biomarker panel in combination with MRI for prostate cancer diagnosisTim M Govers, Matthew J Resnick, Ardeshir R Rastinehad, et al.
BJUI Compass|March 19, 2025
Genomic prostate score and treatment selection in favourable intermediate-risk prostate cancerEric Margolis, Benjamin H Lowentritt, Christopher M Pieczonka, et al.
The Journal of Urology|September 21, 2010
PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trialSheila M J Aubin, Jennifer Reid, Mark J Sarno, et al.
Urology|August 9, 2011
Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trialSheila M J Aubin, Jennifer Reid, Mark J Sarno, et al.
The Journal of Urology|August 19, 2008
Predicting prostate cancer risk through incorporation of prostate cancer gene 3Donna Pauler Ankerst, Jack Groskopf, John R Day, et al.
The Journal of Urology|April 27, 2019
Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate BiopsyAlexander Haese, Geert Trooskens, Sandra Steyaert, et al.
Urology Practice|June 15, 2023
Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical PracticeNeal Shore, Jason Hafron, Timothy Langford, et al.
The Journal of Urology|March 21, 2008
PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillanceHiroyuki Nakanishi, Jack Groskopf, Herbert A Fritsche, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Cancer Letters|November 25, 2010
PCA3: from basic molecular science to the clinical labJohn R Day, Matthias Jost, Mark A Reynolds, et al.
Cancer Letters|February 17, 2007
Molecular markers for prostate cancerMark A Reynolds, Kumar Kastury, Jack Groskopf, et al.
World Journal of Urology|May 3, 2023
Cost-effectiveness of an urinary biomarker panel in combination with MRI for prostate cancer diagnosisTim M Govers, Matthew J Resnick, Ardeshir R Rastinehad, et al.
BJUI Compass|March 19, 2025
Genomic prostate score and treatment selection in favourable intermediate-risk prostate cancerEric Margolis, Benjamin H Lowentritt, Christopher M Pieczonka, et al.
The Journal of Urology|September 21, 2010
PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trialSheila M J Aubin, Jennifer Reid, Mark J Sarno, et al.
Urology|August 9, 2011
Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trialSheila M J Aubin, Jennifer Reid, Mark J Sarno, et al.
The Journal of Urology|August 19, 2008
Predicting prostate cancer risk through incorporation of prostate cancer gene 3Donna Pauler Ankerst, Jack Groskopf, John R Day, et al.
The Journal of Urology|April 27, 2019
Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate BiopsyAlexander Haese, Geert Trooskens, Sandra Steyaert, et al.
Urology Practice|June 15, 2023
Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical PracticeNeal Shore, Jason Hafron, Timothy Langford, et al.
The Journal of Urology|March 21, 2008
PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillanceHiroyuki Nakanishi, Jack Groskopf, Herbert A Fritsche, et al.
Pageof 3